Patents Assigned to Novagali Pharma SA
  • Publication number: 20130337019
    Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
    Type: Application
    Filed: August 2, 2013
    Publication date: December 19, 2013
    Applicant: NOVAGALI PHARMA SA
    Inventors: LAURA RABINOVICH-GUILATT, GREGORY LAMBERT, FREDERIC LALLEMAND, BETTY PHILIPS
  • Patent number: 8524779
    Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 3, 2013
    Assignee: Novagali Pharma SA
    Inventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
  • Patent number: 8512687
    Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 20, 2013
    Assignee: Novagali Pharma SA
    Inventors: Grégory Lambert, Laura Rabinovich-Guilatt, Frédéric Lallemand, Jean-Sébastien Garrigue, Betty Philips
  • Publication number: 20130164285
    Abstract: The invention relates to a composition for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. The invention also relates to a pharmaceutical composition or to a medicament comprising the composition of the invention, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of the composition of the invention. The invention also relates to a device comprising the composition of the invention.
    Type: Application
    Filed: September 2, 2011
    Publication date: June 27, 2013
    Applicant: NOVAGALI PHARMA SA
    Inventors: Frederic Lallemand, Jean-Sebastien Garrigue, Betty Philips
  • Patent number: 8372434
    Abstract: An ophthalmic oil-in-water type emulsion, which includes colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent, at least one no ionic surfactant, the emulsion having a positive zeta potential and meeting zeta potential stability Test A requirements. Process for making the emulsions. Delivery device selected from the group including lenses, ocular patch, implant, insert, the device containing an emulsion according to the invention.
    Type: Grant
    Filed: October 10, 2005
    Date of Patent: February 12, 2013
    Assignee: Novagali Pharma SA
    Inventors: Séverine Bague, Betty Philips, Laura Rabinovich-Guilatt, Gregory Lambert, Jean-Sébastien Garrigue
  • Patent number: 8298569
    Abstract: Ophthalmic oil-in-water emulsions, which comprises colloid particles having an oily core surrounded by an interfacial film, the emulsion comprising an 10 immunosuppressive agent, an oil, preferably at least 50% of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions, particularly of dry eye diseases.
    Type: Grant
    Filed: October 10, 2005
    Date of Patent: October 30, 2012
    Assignee: Novagali Pharma SA
    Inventors: Betty Philips, Severine Bague, Laura Rabinovich-Guilatt, Gregory Lambert
  • Patent number: 8298568
    Abstract: A well tolerated oil-in-water emulsion useful as a delivery vehicle of hydrophobic ingredients such as pharmaceutical drugs, wherein the emulsion particles have a net positive charge and comprises 0.001 to 0.1% of a cationic agent, 0 to 1% of a non ionic surfactant and 0 to 0.5% of an anionic surfactant.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: October 30, 2012
    Assignee: Novagali Pharma SA
    Inventors: Séverine Bague, Betty Philips, Jean-Sébastien Garrigue, Laura Rabinovich-Guilatt, Gregory Lambert
  • Publication number: 20120238536
    Abstract: Composition comprising at least one fatty acid glycerol ester for use during or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.
    Type: Application
    Filed: November 19, 2010
    Publication date: September 20, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Jeffrey Heier
  • Publication number: 20120225939
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Application
    Filed: November 19, 2010
    Publication date: September 6, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
  • Patent number: 8227452
    Abstract: Use of a composition comprising at least one prodrug of a steroid, preferably of a corticosteroid, for the preparation of an ophthalmic composition intended for the treatment of an ocular condition or disease of a human being or an animal.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: July 24, 2012
    Assignee: Novagali Pharma SA
    Inventors: Laura Rabinovich-Guilatt, Gregory Lambert
  • Publication number: 20120058187
    Abstract: A composition is described herein for administering with a sustained release kinetic a therapeutically effective amount of a therapeutic agent to a subject in need thereof for treating diseases or conditions of the eye, wherein the composition is an water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase, a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase, and wherein the composition is intraocularly injectable, wherein the composition has a density lower than 1. Some embodiments also relate to a pharmaceutical composition or to a medicament comprising a composition described herein, and to a method for treating a condition or disease of the eye comprising administering a therapeutic amount of a composition described herein.
    Type: Application
    Filed: September 3, 2010
    Publication date: March 8, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Frédéric LALLEMAND, Jean-Sébastien GARRIGUE
  • Publication number: 20110319488
    Abstract: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ?2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 29, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
  • Publication number: 20110313038
    Abstract: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ?2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or glaucoma, for promoting growth of eyelashes and/or for treating eyelash hypotrichosis is also described.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 22, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Frederic Lallemand, Betty Phillips, Jean-Sebastien Garrigue
  • Publication number: 20110201689
    Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
    Type: Application
    Filed: April 28, 2011
    Publication date: August 18, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Laura Rabinovich-Guilatt, Grégory Lambert, Frédéric Lallemand, Betty Philips
  • Patent number: 7973081
    Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: July 5, 2011
    Assignee: Novagali Pharma SA
    Inventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
  • Publication number: 20110021443
    Abstract: Oil-in-water emulsion including a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof.
    Type: Application
    Filed: July 29, 2010
    Publication date: January 27, 2011
    Applicant: NOVAGALI PHARMA SA
    Inventors: Grégory LAMBERT, Laura RABINOVICH-GUILATT, Frédéric LALLEMAND, Jean-Sébastien GARRIGUE, Betty PHILIPS
  • Patent number: 7834172
    Abstract: Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: November 16, 2010
    Assignee: Novagali Pharma SA
    Inventors: Gregory Lambert, Frederic Lallemand
  • Publication number: 20100286065
    Abstract: The present invention relates to a new therapeutic approach for the treatment of eye diseases or conditions that allows for the delivery of corticosteroids to the eye's surface but does not cause any of the usual side effects associated with topical administration of corticosteroids. More specifically, the present invention provides methods of treatment involving the administration of a corticosteroid prodrug, such as dexamethasone palmitate, to the surface of the eye. Also provided are pharmaceutical compositions and kits for carrying out such methods of treatment.
    Type: Application
    Filed: December 3, 2008
    Publication date: November 11, 2010
    Applicant: NOVAGALI PHARMA SA
    Inventors: Gregory Lambert, Laura Rabinovich, Frederic Lallemand, Betty Philips
  • Patent number: 7705186
    Abstract: Process for the preparation of unsaturated and saturated primary fatty amines comprising the steps of chlorination, treatment by ammonia, reduction and purification.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: April 27, 2010
    Assignee: Novagali Pharma SA
    Inventor: Scott Gibson
  • Publication number: 20090169629
    Abstract: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions.
    Type: Application
    Filed: January 2, 2008
    Publication date: July 2, 2009
    Applicant: NOVAGALI PHARMA SA
    Inventors: Gregory LAMBERT, Frederic LALLEMAND, Laura RABINOVICH-GUILATT, Severine BAGUE, Jean-Sebastien GARRIGUE